GILEAD SCIENCES, INC.
Follow13F filer, CIK 882095, FOSTER CITY, CA
GILEAD SCIENCES, INC. reported $1,463,841,605 across 5 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-06.
Accepted , ingested 13F-HR 0001123292-26-001479
- Period
- 2026-09-30
- Reported value
- $1.46B
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Part of the filer group GILEAD SCIENCES, INC.
How groups are builtStakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- ASPE ASPEN NEUROSCIENCE INC: 13G 2,879,996 shares, 9.9% of the class, 13G filed 2026-11-06, 0001123292-26-001496Timeline
Accepted , ingested
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001123292-26-001479, largest first. % of portfolio is the value over $1,463,841,605, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| RCUSARCUS BIOSCIENCES INC | 31,424,760 | $812M | 55.45% | 0 | Timeline | ||
| LKFTLAKEFRONT BIOTHERAPEUTICS NV | 16,707,477 | $501M | 34.24% | 0 | Timeline | ||
| ASMBASSEMBLY BIOSCIENCES INC | 4,977,089 | $117M | 7.99% | 0 | Timeline | ||
| KYTXKYVERNA THERAPEUTICS INC | 4,126,119 | $28.1M | 1.92% | 0 | Timeline | ||
| XLOXilio Therapeutics Inc. | 650,389 | $5.89M | 0.4% | 0 | Timeline |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001123292-26-001479 | base | 2026-11-06 |